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S U M M A R Y
Background: The religious seasons of Hajj and Umra in the Kingdom of Saudi Arabia (KSA) have
historically been associated with epidemics of meningococcal disease. Due to the effective preventive
measures taken in recent years, including vaccination, no meningococcal outbreaks have been reported
during Hajj or were Hajj-associated. However, little is known about the immunological proﬁle of
pilgrims. The aim of this study was to assess the immunological proﬁle of pilgrims on arrival in KSA
against the four meningococcal serogroups, A, C, W, and Y, contained within the quadrivalent vaccine.
Methods: Following consent, socio-demographic factors and health-related information was collected
from pilgrims arriving at King Abdul Aziz International Airport and a blood sample taken. Antibodies
were quantiﬁed by serum bactericidal antibody assay using baby rabbit complement (rSBA) against the
four meningococcal serogroups, A, C, W, and Y.
Results: Serum samples were collected from 796 pilgrims; rSBA results were obtained for all four
serogroups for 741 of these samples. A total of 48 (6.5%) Hajjis had previously attended Hajj, ranging
from 1 to 14 times (median 2 times); 98.2% had received meningococcal quadrivalent vaccine in the last
3 years. Of the 13 who had not, all originated from Bangladesh, with four reporting no previous
meningococcal vaccination and nine reporting having received the vaccination more than 3 years ago.
For serogroup A, only one pilgrim from Indonesia had an rSBA titre <8. For serogroups C, W, and Y, the
percentages of pilgrims with rSBA titres <8 were 9.9%, 17.4%, and 9.4%, respectively. Of note was the high
prevalence of non-complement-mediated lysis in pilgrims originating from Nigeria (28/47; 59.6%) and
Afghanistan (21/47; 44.7%), but not the other countries. This may be a reﬂection of the type and pattern
of antibiotic usage among these communities.
Conclusion: The vast majority of pilgrims are vaccinated and protected against meningococcal
serogroups A, C, W, and Y.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mass gatherings continue to draw ever larger crowds from all
corners of the globe and these pose several signiﬁcant public
health challenges to the health and security authorities both
within the host country and abroad. Thus, the introduction,
transmission, and implication of infectious diseases during and
after mass gathering events remain serious public health* Corresponding author.
E-mail address: zmemish@yahoo.com (Z.A. Memish).
http://dx.doi.org/10.1016/j.ijid.2014.09.005
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).concerns.1,2 Epidemics of meningococcal disease have been
associated with the religious seasons of Hajj and Umra in the
Kingdom of Saudi Arabia (KSA), historically caused by serogroup A,
but in the 2000s by serogroup W.3,4 Due to the effective preventive
measures taken in recent years, no meningococcal outbreaks have
been reported during Hajj or have been Hajj-associated.
The main preventive measures taken by the Saudi Health
authorities include mandatory vaccination of pilgrims (domestic
and international) with meningococcal quadrivalent vaccine, no
more than 3 years and no less than 10 days before arrival in KSA,
and the administration of a single dose of ciproﬂoxacin as
chemoprophylaxis against meningococcal carriage for pilgrimsciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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nasopharyngeal carriage rates, as evidenced in a study of Iranian
pilgrims administered 500 mg of ciproﬂoxacin 24 h before
returning home. Carriage rates were 8.5% before departure from
Hajj, decreasing to zero on return, post ciproﬂoxacin.6
The aim of this study was to assess the immunological proﬁle of
pilgrims on arrival in KSA against the four meningococcal
serogroups, A, C, W, and Y, contained within the quadrivalent
vaccine.
2. Methods
2.1. Study area
King Abdul Aziz International (KAAI) Airport is located in
Jeddah and occupies an area of 105 km2. This airport is the
gateway to Makkah, through which most of the international
pilgrims reach the Sacred Mosque in Makkah. The Hajj terminal
of KAAI Airport is designed in the form of tents occupying an area
of 465 000 m2. It is the fourth largest airport terminal in the
world after Hong Kong, Bangkok, and Seoul. It can receive about
50 000 pilgrims a day in the Hajj season. Each of its 12 halls acts
as an arrival lounge for one ﬂight of pilgrims coming to perform
the Hajj, and the same hall acts as a departure lounge for
departing pilgrims. A team from preventive medicine is posted
in each hall, around the clock, during the arrival of pilgrims.
This team reviews the vaccination cards, administers polio
drops and/or ciproﬂoxacin tablets, and performs other special
preventive activities, in accordance with the national policy.
2.2. Ethics
Approval for this study was gained from the Institutional
Review Board of King Fahad Medical City.
2.3. Study population
The study population included Hajjis who were arriving
through KAAI Airport in Jeddah to perform the Hajj in the Islamic
year 1433H (23 September to 20 October 2012). InternationalTable 1
Characteristics of Hajjis from whom sufﬁcient serum sample volumes were obtained
Country Number of sufﬁcient
serum samples
collected from Hajjis
First Hajj (%) Previous inﬂuenza
vaccination (%)
Previo
vaccin
High
Nigeria 47 46 (97.8) 0 (0) 0 (0)
Sudan 20 15 (75.0) 0 (0) 0 (0)
Ethiopia 8 8 (100) 0 (0) 0 (0)
Niger 63 54 (85.7) 6 (1.6) 0 (0)
Subtotal 138 123 (89.1) 6 (4.3) 0 (0)
Medium
India 99 94 (94.9) 0 (0) 0 (0)
Pakistan 105 93 (88.6) 105 (100) 2 (1.9
Bangladesh 75 69 (92.0) 48 (69.6) 0 (0)
Afghanistan 47 46 (97.9) 46 (97.9) 0 (0)
Kazakhstan 6 5 (83.3) 0 (0) 0 (0)
Tajikistan 13 13 (100) 0 (0) 0 (0)
Subtotal 345 320 (92.8) 199 (57.7) 2 (0.6
Low
Indonesia 138 137 (99.3) 137 (99.3) 0 (0)
Turkey 89 89 (100) 0 (0) 0 (0)
Malaysia 14 12 (85.7) 8 (57.1) 8 (57
UK 8 6 (75.0) 0 (0) 0 (0)
France 9 6 (66.7) 0 (0) 0 (0)
Subtotal 258 250 (96.9) 145 (56.2) 8 (3.1
Total 741 693 (93.5) 350 (47.2) 10 (1.3Hajjis were stratiﬁed into three groups based on the presumed
meningococcal disease endemicity level of the country from which
they had arrived (Table 1).
Each identiﬁed pilgrim from a target country was requested to
participate in the study. In the case of refusal, the next pilgrim was
asked for consent. Inclusion criteria were Hajji, willing to
participate, and age over 18 years; only Hajjis from countries that
send more than 5000 pilgrims were included in the study. Hajjis
who refused to participate and those who had already received
chemoprophylaxis were excluded.
In the absence of a clear estimate of valid vaccination and
immunity status against Neisseria meningitidis, a prevalence of 50%
was used to obtain the largest sample size for a given level of
percent point precision. A sample size of 861 was required to
estimate the immunity status to within 3% of this value at a
conﬁdence level of 95%. To obtain blood samples to determine
immunity status, a systematic random sampling technique was
used.
After obtaining verbal informed consent, a questionnaire was
given to the Hajji to be completed by a Ministry of Health
physician. This questionnaire was designed to collect information
including socio-demographic factors (age, gender, and the country
from which they had arrived), health-related information (history
of chronic diseases, receiving immunization against inﬂuenza and
meningococcal disease), information on the validity of the
meningococcal vaccination certiﬁcate, and ciproﬂoxacin tablet
administration in their own country and/or in KSA. All question-
naires were prepared in English, and were then translated into
multiple languages including Hausa, French, Urdu, Hindi, Bengali,
Indonesian, Russian, Malay, Pashto, and Turkish.
2.4. Serology
Blood samples (clotted) were collected from pilgrims (before
the administration of ciproﬂoxacin), in accordance with World
Health Organization (WHO) guidelines, and transported to the
airport primary health care in cold boxes at a temperature between
+2 and +8 8C. These were then dispatched to Public Health England,
Manchester, UK for testing with the serum bactericidal antibody
(SBA) assay for serogroups A, C, W, and Y. Serogroup-speciﬁcus pneumococcal
ation (%)
Previous meningococcal
vaccination in the
last 3 years
Serum bactericidal
antibody control for
non-complement-mediated lysis
failed for one or more strain
 47 (100) 28 (59.6)
 20 (100) 1 (5.0)
 8 (100) 0 (0)
 63 (100) 3 (4.8)
 138 (100) 32 (23.2)
 99 (100) 3 (3.0)
) 105 (100) 7 (6.7)
 62 (82.7) 5 (6.7)
 47 (100) 21 (44.7)
 6 (100) 0 (0)
 13 (100) 1 (7.7)
) 332 (96.2) 37 (10.7)
 138 (100) 1 (0.7)
 89 (100) 1 (1.1)
.1) 14 (100) 0 (0)
 8 (100) 0 (0)
 9 (100) 0 (0)
) 258 (100) 2 (0.8)
) 728 (98.2) 71 (9.6)
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rabbit complement (rSBA; Pel-Freez Inc., Rodgerson, AZ, USA) as an
exogenous complement source, as described elsewhere.7 The
following strains were used (name, strain, and standardized strain
characterization in parenthesis): serogroup A, F8238 (A:4:P1.20,9);
serogroup C, C11 (C:16:P1.7-1,1); serogroup W, M,01.240070
(W:NT:P1.18-1,3); and serogroup Y, M,03.241125 (also known as
S1975) (Y:2a:P1.5,2). rSBA titres were expressed as the reciprocal
of the ﬁnal serum dilution yielding 50% killing at 60 min. For
computational purposes, rSBA titres of <4 were assigned a value of
2. The rSBA contains a control for non-complement-mediated lysis.
If the control failed then the test was repeated at an appropriate
starting dilution, with beta-lactamase. The beta-lactamase is
utilized to remove any antibiotics speciﬁcally from the penicillin-
ase family. If the control still failed then the serum sample was
excluded from the analysis of the rSBA geometric mean titres
(GMTs) and percentages over certain thresholds.
3. Results
A total of 796 out of the 861 pilgrims had serum samples
collected. rSBA results were obtained for all four serogroups for
741 pilgrims; 55 serum samples were insufﬁcient in volume for
one or more serogroups. Data from these 55 serum samples were
omitted from the analyses.
For pilgrims who had their age recorded, this ranged from 18 to
92 years (median 52 years); the age of 16 pilgrims was not
recorded. A total of 64.4% were male, 32.5% female, with gender not
recorded for 3.1%. Details of the country of origin, prior attendance
at Hajj, previous inﬂuenza and pneumococcal vaccines, and prior
meningococcal vaccine are given in Table 1. A total of 48 (6.5%)
Hajjis had previously attended Hajj, ranging from 1 to 14 times
(median 2 times). Overall 47.2% of Hajjis reported prior inﬂuenza
vaccination, although this varied considerably by country. Only
1.3% of pilgrims had previously received pneumococcal vaccination.
A total of 98.2% of pilgrims had received meningococcal quadrivalent
vaccine in the last 3 years. Of the 13 who had not, all originated from
Bangladesh, with four reporting no previous meningococcal
vaccination and nine reporting vaccination more than 3 years ago.
For the four pilgrims who reported no previous meningococcal
vaccination, the number with rSBA titres 8 for serogroups A, C, W,
and Y were 4 (100%), 4 (100%), 3 (75.5%), and 3 (75.0%),
respectively, whilst for 128 the corresponding numbers were 40%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
A C W Y A C W Y A C W Y A C W Y A C W Y A C W Y A C W Y A C W
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Figure 1. Percentages of serogroup A, C, W, and Y serum bactericidal antibody titres at diff
for serogroup C is a titre of 8.(100%), 4 (100%), 1 (25.0%), and 3 (75.0%), respectively. With
regards to the nine pilgrims who reported meningococcal
vaccination more than 3 years ago, one showed non-comple-
ment-mediated lysis; of the remaining eight, the number with
rSBA titres 8 for serogroups A, C, W, and Y were 8 (100%), 3
(37.5%), 5 (62.5%), and 2 (25.0%), respectively, whilst for 128
the corresponding numbers were 7 (87.5%), 3 (37.5%), 5 (62.5%),
and 2 (25.0%), respectively.
The number of sera for which the control failed due to non-
complement-mediated lysis is given in Table 1. These sera were all
excluded from the subsequent analyses. Hajjis from Afghanistan
and Nigeria had high percentages of control fails, at 44.7% and
59.6%, respectively.
The percentages of rSBA titres at <8, 8–64, 128–512, 1024–
4096, and >4096 by country of origin of the pilgrims are given in
Figure 1. For serogroup A, only one pilgrim from Indonesia had an
rSBA titre <8. For serogroup C, the percentage of pilgrims with
rSBA titres <8 was 0.4% (3/741), ranging from 0% in pilgrims from
France (0/9) and Malaysia (0/14) to 50% (3/6) in those from
Kazakhstan. For serogroup W, 17.4% of all pilgrims had rSBA titres
<8, ranging from 2.9% (4/137) to 75% (6/8) in pilgrims from
Indonesia and Ethiopia, respectively. For serogroup Y, 9.4% of all
pilgrims had rSBA titres <8, ranging from 0% in those from France
(0/9), Sudan (0/19), and the UK (0/8) to 37.5% (3/8) in those from
Ethiopia.
The serogroup A, C, W, and Y rSBA GMTs are given in
Figure 2. For serogroup A, the rSBA GMTs (95% conﬁdence interval
(CI)) ranged from 444.7 (95% CI 98.7–2003.5) to 4933.4 (95% CI
2710.0–8980.8) for pilgrims from Kazakhstan and France, respec-
tively. For serogroup C, rSBA GMTs ranged from 8.0 (95% CI 0.4–
176.6) to 3254.4 (95% CI 2307.8–4589.5) for pilgrims from
Kazakhstan and India, respectively. The lowest serogroup W rSBA
GMT was seen in pilgrims from Ethiopia at 3.4 (95% CI 0.4–26.9),
whilst the highest was seen in those from Indonesia at 5727.7 (95%
CI 3948.9–8307.9). For serogroup Y, rSBA GMTs ranged from 20.1
(95% CI 1.6–245.6) to 5162.6 (95% CI 3966.6–6719.1) in pilgrims
from Ethiopia and Indonesia, respectively.
Figure 3 depicts the serogroup A, C, W, and Y rSBA GMTs by age
group: 18–27 years (n = 16), 28–37 years (n = 86), 38–47 years
(n = 154), 48–57 years (n = 169), 58–67 years (n = 164), >68 years
(n = 64), and age unknown (n = 15) (data not analysed). No trends
in rSBA GMT were observed for serogroups A, C, and Y. For
serogroup W, the youngest age group, 18–27 years, had the highest Y A C W Y A C W Y A C W Y A C W Y A C W Y A C W Y A C W Y
ia Niger Nigeria Pakistan Sud an Tajikistan Turkey UK
1024-4096 >409 6
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erent thresholds by country of pilgrim origin. The putative protective rSBA threshold
Figure 2. Serogroup A, C, W, and Y geometric mean titres and 95% conﬁdence intervals by country of pilgrim origin.
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years had the lowest rSBA GMT of 53.2 (95% CI 23.1–122.5).
4. Discussion
Vaccination with meningococcal quadrivalent ACWY vaccine is
required for all pilgrims coming to KSA regardless of their country
of origin. Pilgrims should show evidence of vaccination no more
than 3 years and no less than 10 days before arrival in KSA. In this
study, 98.2% of pilgrims were vaccinated with ACWY vaccine; of
interest, all of those who were not vaccinated originated from
Bangladesh. In a study of Hajj pilgrims in 2013, it was reported that
93% of pilgrims had been vaccinated with ACWY vaccine.8 In the
latter report, 4.4% had received pneumococcal vaccination and 22%
had received inﬂuenza vaccination as compared to 1.3% and 47.2%,
respectively, in the present study.
Provision of a history of meningococcal vaccination does not
indicate deﬁnitive protection, and the absence of vaccination does
not infer that an individual may not be protected, as natural
immunity also protects individuals.9 However, by using the
correlate of protection – the rSBA assay – insight can be gainedFigure 3. Serogroup A, C, W, and Y geometric mean titrinto the percentage of persons protected.10 Of note, of the four
pilgrims for whom serology was available who had not been
vaccinated with ACWY, only one was unprotected against
serogroup Y and one against serogroup W. Of those who reported
vaccination, only one pilgrim was unprotected against serogroup
A, but 9.9%, 17.4%, and 9.4% were unprotected against serogroups C,
W, and Y, respectively.
Putative protection for serogroup A was excellent, with only
one pilgrim having an rSBA titre <8; however, for serogroups C, W,
and Y the percentage of pilgrims protected varied by country. For
serogroup C, only 50% of pilgrims from Kazakhstan had rSBA titres
8, although it should be noted that only six pilgrims from this
country were enrolled in the study. For serogroups Y and W, the
highest percentage of pilgrims with rSBA titres <8 was found in
those attending from Ethiopia, 37.5% and 75.0%, respectively,
although only a total of eight pilgrims were enrolled from that
country.
The SBA assay is a bioassay utilizing live meningococci, thus if a
serum sample contains antibiotics, these meningococci will be
lysed even in the absence of complement. Hence all SBA assays
contain a control that measures non-complement-mediatedes and 95% conﬁdence intervals by age of pilgrim.
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beta-lactamase is added, which shows speciﬁcity for penicillins
by hydrolyzing the beta-lactam ring. However, for other classes
of antibiotic, no easy solution is available and SBA titres cannot
be gained. Of note in this study was the high prevalence of
non-complement-mediated lysis in pilgrims originating from
Nigeria (59.6%) and Afghanistan (44.7%), but not the other
countries. This may well be due to the use of antibiotics
and related to the antimicrobial stewardship and availability in
those countries.
One drawback of this study is that data on the type of
meningococcal vaccine – polysaccharide versus conjugate – were
not collected. Although both types of vaccine are immunogenic in
this age group, conjugates elicit high avidity antibodies and tend to
higher SBA levels to all serogroups than the polysaccharide
vaccines.12,13 Given that the cost of conjugate vaccines is higher
than that of the polysaccharide vaccines and the polysaccharide
vaccines are easily accessible, it may be that the use of
polysaccharide vaccines was higher in the less developed
countries, particularly those of Sub-Saharan Africa.
Notwithstanding this limitation, with regards to meningococcal
vaccination and protection against meningococcal disease, we
found that the vast majority of pilgrims are vaccinated and
protected.
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